Company: INSP
Filing Date: 2025-03-18
Form Type: DEF 14A
Source: 0001140361-25-009249
Chunk: 40

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-03-18
Form: DEF 14A
Chunk 40
---
 will consider the outcome of this vote in making future compensation decisions for our NEOs. Accordingly, we ask our stockholders to vote “FOR” the following resolution at the Annual Meeting: “RESOLVED, that the stockholders of Inspire Medical Systems, Inc. approve, on an advisory basis, the fiscal 2024 compensation of Inspire Medical Systems, Inc.’s named executive officers as described in the “Executive Compensation” section and disclosed in the Summary Compensation Table and related compensation tables and narrative disclosure set forth in Inspire Medical Systems, Inc.’s Proxy Statement for the 2025 Annual Meeting of Stockholders.” Recommendation of the Board of Directors

| OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE RESOLUTION TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NEOS. |

| Inspire Medical Systems, Inc. |     | 34 |     | 2025 Proxy Statement |

TABLE OF CONTENTS

Executive Compensation Compensation Discussion and Analysis EXECUTIVE SUMMARY In this Compensation Discussion and Analysis (“CD&A”), we provide an overview of the compensation awarded to or earned by our named executive officers (“NEOs”) identified below during fiscal 2024. The following discussion and analysis details the Company’s philosophy and policies regarding executive compensation, the process that is used to set executive compensation within the Company, the elements of the executive compensation program, and other elements and aspects of our executive compensation program. In fiscal 2024, our “named executive officers” were as follows:

| • | Timothy P. Herbert, who served as President and CEO |

| • | Richard J. Buchholz, who served as Chief Financial Officer |

| • | Randall A. Ban, who served as Chief Commercial Officer |

| • | Bryan K. Phillips, who served as SVP, General Counsel, Chief Compliance Officer and Corporate Secretary |

| • | Carlton W. Weatherby, who served as Chief Strategy Officer |

Organizational Changes . In January 2025, we announced a new organizational structure intended to drive our continued growth. Under the new organizational structure, Mr. Weatherby assumed the expanded role of Chief Strategy and Growth Officer with responsibility for the Company’s U.S. Sales, Marketing, and Strategy teams. Mr. Ban assumed the newly created role of Executive Vice President, Patient Access and Therapy Development with responsibility for the Company’s Patient Access and Therapy Development team and Sales team located outside of the U.S. FISC